Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Green Cross Holdings Preferred Stock (005257:KRX), powered by AI.
Green Cross Holdings Preferred Stock is currently trading at ₩20,500. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Green Cross Holdings Preferred Stock on Alpha Lenz.
Green Cross Holdings Preferred Stock's P/E ratio is -13.4.
“Green Cross Holdings Preferred Stock trades at a P/E of -13.4 (undervalued) with modest ROE of -7.3%.”
Ask for details →Green Cross Holdings Preferred Stock is a type of equity security issued by Green Cross Holdings, a prominent company in the biotechnology and pharmaceutical industry based in South Korea. Preferred stocks like these are designed to provide investors with a degree of income stability, as they typically offer fixed dividends. Unlike common stock, holders of preferred stock do not usually have voting rights in corporate decisions, but they are often afforded a higher claim on assets and earnings, especially in the event of liquidation. In the financial market, Green Cross Holdings Preferred Stock plays a crucial role by attracting investors who seek a reliable income stream along with potential upside exposure to the biopharmaceutical sector. The company is known for its advancements in healthcare solutions, including vaccines and pharmaceuticals, making this stock a significant component of portfolios focusing on healthcare investments. As such, it contributes to the broader market's diversification and stability by providing alternative investment opportunities alongside traditional stocks and bonds.
“Green Cross Holdings Preferred Stock trades at a P/E of -13.4 (undervalued) with modest ROE of -7.3%.”
Ask for details →Green Cross Holdings Preferred Stock (ticker: 005257) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 141 employees. Market cap is $17.3B.
The current price is ₩20,500 with a P/E ratio of -13.39x and P/B of 1.03x.
ROE is -7.34% and operating margin is 1.49%. Annual revenue is $2.5T.